デフォルト表紙
市場調査レポート
商品コード
1409839

全身性エリテマトーデス治療の世界市場レポート 2024年

Systemic Lupus Erythematosus Treatment Global Market Report 2024

出版日: 受注後更新 | 発行: The Business Research Company | ページ情報: 英文 200 Pages | 納期: 2~10営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.49円
全身性エリテマトーデス治療の世界市場レポート 2024年
出版日: 受注後更新
発行: The Business Research Company
ページ情報: 英文 200 Pages
納期: 2~10営業日
ご注意事項 :
本レポートの納品は、最新情報反映のため受注時に適宜更新しお届けいたします。
更新情報の反映作業にあたり納期もレポート毎に異なりますので、ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

全身性エリテマトーデス治療の市場規模は近年急速に拡大しています。2023年の27億6,000万米ドルから2024年には30億6,000万米ドルへと、CAGR10.7%で拡大する見込みです。この成長は、全身性エリテマトーデス(SLE)治療のための生物学的製剤や標的治療薬の大幅な進歩、疾患メカニズムに対する理解の深まり、ループス治療に焦点を当てた広範な臨床試験や研究イニシアティブ、ループスを含む希少疾患治療への対処を目的とした政府のイニシアティブ、より多くの症例が特定され診断されるに至った認知度の向上と診断能力の向上など、いくつかの要因によるものです。

全身性エリテマトーデス治療市場規模は、今後数年で急成長が見込まれます。2028年にはCAGR11.1%で46億6,000万米ドルに成長します。予測期間中に予想される成長は、全身性エリテマトーデス(SLE)治療用に調整されたバイオシミラーの出現、ループス管理へのデジタルヘルスソリューションの導入、ループスケアにおける補完代替医療への注目の高まり、免疫調節療法における継続的な技術革新、患者擁護・支援団体の積極的な役割など、いくつかの要因に関連しています。この期間に予想される主な動向には、SLEに対するコンビナトリアル療法の利用、個々の患者のニーズに対応する個別化医療のアプローチ、ループス治療におけるバイオシミラーの使用の増加、SLE管理診療への遠隔医療の統合、ループス患者のエンパワーメントを目的とした教育イニシアティブ、ループス治療および管理に特化した研究を促進する世界の共同研究の増加が含まれます。

予測される自己免疫疾患の急増は、全身性エリテマトーデス治療市場の拡大を促進します。自己免疫疾患は、免疫系が誤って体内組織を攻撃し、健康な細胞を標的とする自己抗体を放出することで発症します。著名な自己免疫疾患である全身性エリテマトーデスは、関節、皮膚、脳、肺、腎臓、血管などの罹患臓器に広範な炎症と組織損傷を引き起こします。2023年5月現在、オックスフォード大学は、自己免疫疾患が世界人口の10%に影響を与え、女性の13%、男性の7%が罹患していることを明らかにしています。同様に、ロンドン大学シティ校が2021年10月に発表したデータによると、英国では約400万人(人口の7%)が少なくとも1つの自己免疫疾患に罹患していると推定されています。80を超える自己免疫疾患が確認されており、有病率は毎年3~9%増加していることから、自己免疫疾患の発生率の上昇が全身性エリテマトーデス治療市場の主要促進要因となっています。

全身性エリテマトーデス治療市場の成長予測は、ヘルスケア支出の増加によってさらに促進されます。ヘルスケア支出は、特定のヘルスケアシステムまたは経済圏におけるヘルスケアサービス、商品、関連活動に対する一定期間の総支出額を意味します。このような財政支援は、研究開発、革新的治療法へのアクセス、広範な臨床試験、患者ケアと転帰の全体的な強化を促進することにより、全身性エリテマトーデス治療の強固なエコシステムを構築します。注目すべきは、2023年5月の英国の国家統計局の報告によると、ヘルスケア支出は名目9.4%増、実質9.7%増となっていることです。2021年の英国の総医療費は3,672億5,000万米ドル(2,807億円)に達し、そのうち医薬品費は518億4,000万米ドル(396億円)にのぼる。予防医療費が大幅に増加し、459億3,000万米ドル(351億ポンド)に達したことは、全身性エリテマトーデス治療市場を推進する上で、ヘルスケア支出の増加が極めて重要な役割を果たしていることを裏付けています。

北米は、2023年の全身性エリテマトーデス治療市場において最大の地域でした。全身性エリテマトーデス治療市場レポートの対象地域は、アジア太平洋、西欧、東欧、北米、南米、中東・アフリカです。

目次

第1章 エグゼクティブサマリー

第2章 全身性エリテマトーデス治療市場の特徴

第3章 全身性エリテマトーデス治療市場の動向と戦略

第4章 全身性エリテマトーデス治療市場- マクロ経済シナリオ

  • 高インフレが市場に与える影響
  • ウクライナ・ロシア戦争が市場に与える影響
  • COVID-19による市場への影響

第5章 世界の全身性エリテマトーデス治療市場規模と成長

  • 世界の市場促進要因と抑制要因
    • 市場促進要因
    • 市場抑制要因
  • 世界の市場規模実績と成長、2018年~2023年
  • 世界の市場規模予測と成長、2023年~2028年、2033年

第6章 全身性エリテマトーデス治療市場セグメンテーション

  • 世界の全身性エリテマトーデス治療市場、薬剤別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 抗マラリア薬
  • 非ステロイド性抗炎症薬(NSAIDS)
  • コルチコステロイド
  • 免疫抑制薬
  • 世界の全身性エリテマトーデス治療市場、投与経路別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 皮下
  • 経口
  • 静脈内
  • 世界の全身性エリテマトーデス治療市場、用途別セグメンテーション、実績および予測、2018-2023年、2023-2028年、2033年
  • 病院薬局
  • 小売薬局
  • オンライン販売

第7章 全身性エリテマトーデス治療市場の地域および国分析

  • 世界の全身性エリテマトーデス治療市場、地域別、実績および予測、2018-2023年、2023-2028年、2033年
  • 世界の全身性エリテマトーデス治療市場、国別、実績および予測、2018-2023年、2023-2028年、2033年

第8章 アジア太平洋の全身性エリテマトーデス治療市場

第9章 中国の全身性エリテマトーデス治療市場

第10章 インドの全身性エリテマトーデス治療市場

第11章 日本の全身性エリテマトーデス治療市場

第12章 オーストラリアの全身性エリテマトーデス治療市場

第13章 インドネシアの全身性エリテマトーデス治療市場

第14章 韓国の全身性エリテマトーデス治療市場

第15章 西欧の全身性エリテマトーデス治療市場

第16章 英国の全身性エリテマトーデス治療市場

第17章 ドイツの全身性エリテマトーデス治療市場

第18章 フランスの全身性エリテマトーデス治療市場

第19章 イタリアの全身性エリテマトーデス治療市場

第20章 スペインの全身性エリテマトーデス治療市場

第21章 東欧の全身性エリテマトーデス治療市場

第22章 ロシアの全身性エリテマトーデス治療市場

第23章 北米の全身性エリテマトーデス治療市場

第24章 米国の全身性エリテマトーデス治療市場

第25章 カナダの全身性エリテマトーデス治療市場

第26章 南米の全身性エリテマトーデス治療市場

第27章 ブラジルの全身性エリテマトーデス治療市場

第28章 中東の全身性エリテマトーデス治療市場

第29章 アフリカの全身性エリテマトーデス治療市場

第30章 全身性エリテマトーデス治療市場の競合情勢と企業プロファイル

  • 全身性エリテマトーデス治療市場の競合情勢
  • 全身性エリテマトーデス治療市場の企業プロファイル
    • GlaxoSmithKline plc
    • Aurinia Pharmaceuticals Inc.
    • Pfizer Inc.
    • Merck &Co Inc.
    • Anthera Pharmaceuticals Inc.

第31章 世界の全身性エリテマトーデス治療市場の競合ベンチマーキング

第32章 世界の全身性エリテマトーデス治療市場競争力ダッシュボード

第33章 全身性エリテマトーデス治療市場における主要な合併と買収

第34章 全身性エリテマトーデス治療市場の将来展望と可能性分析

第35章 付録

目次
Product Code: r11377

“Systemic Lupus Erythematosus Treatment Global Market Report 2024 ” from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on systemic lupus erythematosus treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
  • Assess the Russia - Ukraine war's impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for systemic lupus erythematosus treatment? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? “The systemic lupus erythematosus treatment market global report ” from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Scope

Markets Covered:

  • 1) By Drug: Antimalarial Drugs; Non-Steroidal Anti-Inflammatory Drugs (NSAIDS); Corticosteroids; Immunosuppressive Drugs
  • 2) By Route Of Administration: Sub-Cutaneous; Oral; Intravenous
  • 3) By Application: Hospital Pharmacies; Retail Pharmacies; Online Sales
  • Companies Mentioned: GlaxoSmithKline plc; Aurania Pharmaceuticals Inc.; Pfizer Inc.; Merck & Co Inc.; Anthera Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Executive Summary

Systemic lupus erythematosus (SLE) is an autoimmune disease that prompts the immune system to attack the body's own tissues, leading to widespread inflammation and damage in multiple organs including the joints, skin, brain, lungs, kidneys, and blood vessels. While it cannot be cured, medical treatments and lifestyle adjustments can help manage the condition. The treatment primarily involves the use of drugs that suppress the overactive immune response.

The main categories of drugs used in treating systemic lupus erythematosus include antimalarial drugs, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, and immunosuppressive drugs. Antimalarial medications such as hydroxychloroquine (Plaquenil), chloroquine (Aralen), and quinacrine (Atabrine) have shown efficacy in managing lupus symptoms. These drugs are administered through various routes including subcutaneous, oral, and intravenous methods. Treatments for SLE are available through diverse channels including hospital pharmacies, retail pharmacies, and online sales.

The systemic lupus erythematosus treatment market research report is one of a series of new reports from The Business Research Company that provides systemic lupus erythematosus treatment market statistics, including systemic lupus erythematosus treatment industry global market size, regional shares, competitors with a systemic lupus erythematosus treatment market share, detailed systemic lupus erythematosus treatment market segments, market trends and opportunities, and any further data you may need to thrive in the systemic lupus erythematosus treatment industry. This systemic lupus erythematosus treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The systemic lupus erythematosus treatment market size has grown rapidly in recent years. It will grow from $2.76 billion in 2023 to $3.06 billion in 2024 at a compound annual growth rate (CAGR) of 10.7%. The growth observed in the historical period can be attributed to several factors, including significant advancements in biologics and targeted therapies designed for treating systemic lupus erythematosus (SLE), a heightened understanding of the disease mechanisms, extensive clinical trials and research initiatives focusing on lupus treatments, governmental initiatives aimed at addressing rare disease treatments including lupus, and increased awareness and improved diagnostic capabilities leading to more cases being identified and diagnosed.

The systemic lupus erythematosus treatment market size is expected to see rapid growth in the next few years. It will grow to $4.66 billion in 2028 at a compound annual growth rate (CAGR) of 11.1%. The anticipated growth in the forecast period can be linked to several factors, including the emergence of biosimilars tailored for treating systemic lupus erythematosus (SLE), the incorporation of digital health solutions into lupus management, an increased focus on complementary and alternative medicine in lupus care, ongoing innovations in immunomodulatory therapies, and the proactive role of patient advocacy and support organizations. Key trends expected in this period encompass the utilization of combinatorial therapies for SLE, personalized medicine approaches catering to individual patient needs, the increasing use of biosimilars in treating lupus, the integration of telemedicine into SLE management practices, educational initiatives aimed at empowering lupus patients, and a rise in global collaborations fostering research dedicated to lupus treatment and management.

The anticipated surge in autoimmune disorders is set to drive the expansion of the systemic lupus erythematosus treatment market. Autoimmune diseases manifest when the immune system erroneously attacks the body's own tissues, releasing autoantibodies that target healthy cells. Systemic lupus erythematosus, a prominent autoimmune disease, leads to widespread inflammation and tissue damage in affected organs, including joints, skin, brain, lungs, kidneys, and blood vessels. As of May 2023, the University of Oxford reveals that autoimmune disorders impact 10% of the global population, affecting 13% of women and 7% of men. Similarly, data from October 2021, shared by the City, University of London, indicates that approximately 4 million people in the UK, constituting 7% of the population, are estimated to have at least one autoimmune disease. With over 80 identified autoimmune disorders and an annual increase in prevalence by 3-9%, the escalating incidence of autoimmune disorders is a key driver for the systemic lupus erythematosus treatment market.

The projected growth of the systemic lupus erythematosus treatment market is further fueled by the escalating healthcare expenditure. Healthcare expenditure encompasses the total monetary outlay on healthcare services, goods, and associated activities within a specific healthcare system or economy over a defined period. This financial support creates a robust ecosystem for systemic lupus erythematosus treatment by facilitating research, development, access to innovative therapies, extensive clinical trials, and overall enhancements in patient care and outcomes. Notably, in May 2023, the UK's Office for National Statistics reports a nominal increase of 9.4% and a practical increase of 9.7% in healthcare spending. The total healthcare cost in the UK for 2021 reached $367.25 billion (£280.7 billion), with pharmaceutical costs amounting to $51.84 billion (£39.6 billion). A significant rise in preventative care spending, reaching $45.93 billion (£35.1 billion), underscores the pivotal role of increasing healthcare expenditure in propelling the systemic lupus erythematosus treatment market.

Prominent companies within the systemic lupus erythematosus treatment market are strategically concentrating on securing product approvals, exemplified by Saphnelo, to boost their market revenues. Saphnelo (anifrolumab-fnia) stands as a prescription medicine tailored for adults with systemic lupus erythematosus (SLE) ranging from moderate to severe, who concurrently use other lupus medications. A milestone achievement occurred in August 2021 when AstraZeneca PLC, a Sweden-based pharmaceutical giant, obtained FDA approval for anifrolumab-fnia (Saphnelo). This marked a groundbreaking development as it became the first FDA-approved type I interferon (type I IFN) receptor antagonist. Given the pivotal role of type I interferon signaling in the pathophysiology of lupus, with higher levels associated with more active and severe disease, Saphnelo's approval represents a significant stride in the systemic lupus erythematosus treatment landscape.

Major players in the systemic lupus erythematosus treatment market are strategically pursuing product approvals, with a notable example being Zynrelef (HTX-011), to drive market revenues. Zynrelef, a dual-acting, extended-release local anesthetic comprising bupivacaine and meloxicam, is designed to manage postoperative pain for up to 72 hours. Heron Therapeutics, Inc., a US-based biotechnology company, achieved a significant milestone in May 2021 with the FDA approval of Zynrelef (HTX-011). The medication is recommended for postoperative analgesia up to 72 hours following specific surgical procedures, including foot and ankle, small-to-medium open abdomen, and lower extremity total joint arthroplasty. Clinically proven to substantially reduce opioid usage after surgery and effectively control pain over a 72-hour period, Zynrelef outperforms the standard of care bupivacaine HCl solution, reinforcing its strategic significance in driving revenue growth within the systemic lupus erythematosus treatment market.

In March 2021, Merck, a pharmaceutical company based in the United States, completed the acquisition of Pandion Therapeutics for a total sum of $1.85 billion. This strategic acquisition provided Merck with access to Pandion Therapeutics' TALON technology, a valuable asset aimed at addressing unmet needs in autoimmune conditions by rebalancing the immune response. Pandion Therapeutics, a biotechnology company based in the United States, specializes in the development of innovative therapeutics. The primary focus of the company is on its lead candidate, PT101, which is an engineered IL-2 mutein combined with a protein backbone. PT101 is designed to effectively treat autoimmune diseases, including ulcerative colitis and systemic lupus erythematosus, by activating and expanding Tregs (regulatory T cells).

Major companies operating in the systemic lupus erythematosus treatment market report are GlaxoSmithKline plc, Aurinia Pharmaceuticals Inc., Pfizer Inc., Merck & Co Inc., Anthera Pharmaceuticals Inc., AstraZeneca plc, Bristol-Myers Squibb Company Inc., F. Hoffmann-La Roche Ltd., ImmuPharma plc, Sanofi SA, Eli Lilly and Company, Amgen Inc., Johnson & Johnson Services Inc., Lycera Corporation, Roche Holding AG, Bayer AG, Novartis International AG, Viatris Inc., Swedish Orphan Biovitrum AB, Union Chimique Belge SA, Biogen Inc., Horizon Therapeutics plc, Gilead Sciences Inc., Daiichi Sankyo Company Limited, EMD Serono Inc., Hoth Therapeutics Inc., Zylo Therapeutics Inc., Kyowa Kirin Co. Ltd., Priothera Ltd., Centessa Pharmaceuticals plc, AbbVie Inc., Astellas Pharma Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Eisai Co. Ltd., Mallinckrodt Pharmaceuticals, Regeneron Pharmaceuticals Inc., Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited .

North America was the largest region in the systemic lupus erythematosus treatment market in 2023. The regions covered in the systemic lupus erythematosus treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the systemic lupus erythematosus treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The systemic lupus erythematosus treatment market consists of sales of systemic lupus erythematosus drugs including antimalarial drugs such as chloroquine, and hydrochlorquine, cytotoxic, and immunosuppressive drugs such as cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, tacrolimus, non-steroidal anti-inflammatory drugs such as ibuprofen, naproxen, biologics such as b-cell modulators, t-cell modulators, pro-inflammatory, as well as cytokine inhibitors, corticosteroids such as prednisone, hydrocortisone, dexamethasone, and other drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary

2. Systemic Lupus Erythematosus Treatment Market Characteristics

3. Systemic Lupus Erythematosus Treatment Market Trends And Strategies

4. Systemic Lupus Erythematosus Treatment Market - Macro Economic Scenario

  • 4.1. Impact Of High Inflation On the Market
  • 4.2. Ukraine-Russia War Impact On the Market
  • 4.3. COVID-19 Impact On the Market

5. Global Systemic Lupus Erythematosus Treatment Market Size and Growth

  • 5.1. Global Systemic Lupus Erythematosus Treatment Market Drivers and Restraints
    • 5.1.1. Drivers Of The Market
    • 5.1.2. Restraints Of The Market
  • 5.2. Global Systemic Lupus Erythematosus Treatment Historic Market Size and Growth, 2018 - 2023, Value ($ Billion)
  • 5.3. Global Systemic Lupus Erythematosus Treatment Forecast Market Size and Growth, 2023 - 2028, 2033F, Value ($ Billion)

6. Systemic Lupus Erythematosus Treatment Market Segmentation

  • 6.1. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Antimalarial Drugs
  • Non-Steroidal Anti-Inflammatory Drugs (NSAIDS)
  • Corticosteroids
  • Immunosuppressive Drugs
  • 6.2. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Sub-Cutaneous
  • Oral
  • Intravenous
  • 6.3. Global Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Sales

7. Systemic Lupus Erythematosus Treatment Market Regional And Country Analysis

  • 7.1. Global Systemic Lupus Erythematosus Treatment Market, Split By Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 7.2. Global Systemic Lupus Erythematosus Treatment Market, Split By Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

8. Asia-Pacific Systemic Lupus Erythematosus Treatment Market

  • 8.1. Asia-Pacific Systemic Lupus Erythematosus Treatment Market Overview
  • Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.3. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 8.4. Asia-Pacific Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

9. China Systemic Lupus Erythematosus Treatment Market

  • 9.1. China Systemic Lupus Erythematosus Treatment Market Overview
  • 9.2. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.3. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
  • 9.4. China Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion

10. India Systemic Lupus Erythematosus Treatment Market

  • 10.1. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.2. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 10.3. India Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

11. Japan Systemic Lupus Erythematosus Treatment Market

  • 11.1. Japan Systemic Lupus Erythematosus Treatment Market Overview
  • 11.2. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.3. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 11.4. Japan Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

12. Australia Systemic Lupus Erythematosus Treatment Market

  • 12.1. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.2. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 12.3. Australia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

13. Indonesia Systemic Lupus Erythematosus Treatment Market

  • 13.1. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.2. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 13.3. Indonesia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

14. South Korea Systemic Lupus Erythematosus Treatment Market

  • 14.1. South Korea Systemic Lupus Erythematosus Treatment Market Overview
  • 14.2. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.3. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 14.4. South Korea Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

15. Western Europe Systemic Lupus Erythematosus Treatment Market

  • 15.1. Western Europe Systemic Lupus Erythematosus Treatment Market Overview
  • 15.2. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.3. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 15.4. Western Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

16. UK Systemic Lupus Erythematosus Treatment Market

  • 16.1. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.2. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 16.3. UK Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

17. Germany Systemic Lupus Erythematosus Treatment Market

  • 17.1. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.2. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 17.3. Germany Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

18. France Systemic Lupus Erythematosus Treatment Market

  • 18.1. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.2. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 18.3. France Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

19. Italy Systemic Lupus Erythematosus Treatment Market

  • 19.1. Italy Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.2. Italy Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 19.3. Italy Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

20. Spain Systemic Lupus Erythematosus Treatment Market

  • 20.1. Spain Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.2. Spain Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 20.3. Spain Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

21. Eastern Europe Systemic Lupus Erythematosus Treatment Market

  • 21.1. Eastern Europe Systemic Lupus Erythematosus Treatment Market Overview
  • 21.2. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.3. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 21.4. Eastern Europe Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

22. Russia Systemic Lupus Erythematosus Treatment Market

  • 22.1. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.2. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 22.3. Russia Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

23. North America Systemic Lupus Erythematosus Treatment Market

  • 23.1. North America Systemic Lupus Erythematosus Treatment Market Overview
  • 23.2. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.3. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 23.4. North America Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

24. USA Systemic Lupus Erythematosus Treatment Market

  • 24.1. USA Systemic Lupus Erythematosus Treatment Market Overview
  • 24.2. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.3. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 24.4. USA Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

25. Canada Systemic Lupus Erythematosus Treatment Market

  • 25.1. Canada Systemic Lupus Erythematosus Treatment Market Overview
  • 25.2. Canada Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.3. Canada Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 25.4. Canada Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

26. South America Systemic Lupus Erythematosus Treatment Market

  • 26.1. South America Systemic Lupus Erythematosus Treatment Market Overview
  • 26.2. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.3. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 26.4. South America Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

27. Brazil Systemic Lupus Erythematosus Treatment Market

  • 27.1. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.2. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 27.3. Brazil Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

28. Middle East Systemic Lupus Erythematosus Treatment Market

  • 28.1. Middle East Systemic Lupus Erythematosus Treatment Market Overview
  • 28.2. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.3. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 28.4. Middle East Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

29. Africa Systemic Lupus Erythematosus Treatment Market

  • 29.1. Africa Systemic Lupus Erythematosus Treatment Market Overview
  • 29.2. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Drug, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.3. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Route Of Administration, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • 29.4. Africa Systemic Lupus Erythematosus Treatment Market, Segmentation By Application, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion

30. Systemic Lupus Erythematosus Treatment Market Competitive Landscape And Company Profiles

  • 30.1. Systemic Lupus Erythematosus Treatment Market Competitive Landscape
  • 30.2. Systemic Lupus Erythematosus Treatment Market Company Profiles
    • 30.2.1. GlaxoSmithKline plc
      • 30.2.1.1. Overview
      • 30.2.1.2. Products and Services
      • 30.2.1.3. Strategy
      • 30.2.1.4. Financial Performance
    • 30.2.2. Aurinia Pharmaceuticals Inc.
      • 30.2.2.1. Overview
      • 30.2.2.2. Products and Services
      • 30.2.2.3. Strategy
      • 30.2.2.4. Financial Performance
    • 30.2.3. Pfizer Inc.
      • 30.2.3.1. Overview
      • 30.2.3.2. Products and Services
      • 30.2.3.3. Strategy
      • 30.2.3.4. Financial Performance
    • 30.2.4. Merck & Co Inc.
      • 30.2.4.1. Overview
      • 30.2.4.2. Products and Services
      • 30.2.4.3. Strategy
      • 30.2.4.4. Financial Performance
    • 30.2.5. Anthera Pharmaceuticals Inc.
      • 30.2.5.1. Overview
      • 30.2.5.2. Products and Services
      • 30.2.5.3. Strategy
      • 30.2.5.4. Financial Performance

31. Global Systemic Lupus Erythematosus Treatment Market Competitive Benchmarking

32. Global Systemic Lupus Erythematosus Treatment Market Competitive Dashboard

33. Key Mergers And Acquisitions In The Systemic Lupus Erythematosus Treatment Market

34. Systemic Lupus Erythematosus Treatment Market Future Outlook and Potential Analysis

  • 34.1 Systemic Lupus Erythematosus Treatment Market In 2028 - Countries Offering Most New Opportunities
  • 34.2 Systemic Lupus Erythematosus Treatment Market In 2028 - Segments Offering Most New Opportunities
  • 34.3 Systemic Lupus Erythematosus Treatment Market In 2028 - Growth Strategies
    • 34.3.1 Market Trend Based Strategies
    • 34.3.2 Competitor Strategies

35. Appendix

  • 35.1. Abbreviations
  • 35.2. Currencies
  • 35.3. Historic And Forecast Inflation Rates
  • 35.4. Research Inquiries
  • 35.5. The Business Research Company
  • 35.6. Copyright And Disclaimer